Qule Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 114.00 Cr
- Revenue Growth %
- Profit Growth -10407.07%
- Ebitda 71.63%
- Net Worth 106003.92%
- Total Assets 18.55%
About Qule Pharma
Qule Pharma Private Limited (QPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 November 2020 (Four years and three months 10 days old ). Its registered office is in Visakhapatnam, Andhra Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹114.00 Cr.
Nityananda Kambam, Santhanam Subramanian, and Rama Krishna serve as directors at the Company.
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304AP2020PTC116442
- Company No.
116442
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Nov 2020
- Date of AGM
25 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Qule Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rama Krishna  | Director | 25-Apr-2022 | Current |
| Nityananda Kambam | Director | Current | |
| Santhanam Subramanian | Director | 16-Nov-2020 | Current |
Financial Performance of Qule Pharma.
Qule Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 10407.07% decrease in profit. The company's net worth Soared by an impressive increase of 106003.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Qule Pharma?
In 2023, Qule Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eugia Pharma Specialities LimitedSanthanam Subramanian is a mutual person
Aurobindo Pharma LtdNityananda Kambam is a mutual person
- Aurobindo Antibiotics Private Limited
Nityananda Kambam is a mutual person
- Apl Healthcare Limited
Nityananda Kambam is a mutual person
- Apitoria Pharma Private Limited
Nityananda Kambam and Santhanam Subramanian are mutual person
- Raidurgam Developers Limited
Nityananda Kambam is a mutual person
Charges (Loans)
₹1,140.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 114.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 May 2023 | Others | ₹114.00 Cr | Open |
How Many Employees Work at Qule Pharma?
Qule Pharma has a workforce of 22 employees as of Mar 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Qule Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Qule Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
